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SOX2 is a core pluripotency-associated transcription factor causally related to cancer initiation, 
aggressiveness, and drug resistance by driving the self-renewal and seeding capacity of cancer stem cells 
(CSC). Here, we tested the ability of the clinically proven inhibitor of the lysine-specific demethylase 1 
(LSD1/KDM1A) iadademstat (ORY-100) to target SOX2-driven CSC in breast cancer. Iadademstat blocked 
CSC-driven mammosphere formation in breast cancer cell lines that are dependent on SOX2 expression to 
maintain their CSC phenotype. Iadademstat prevented the activation of an LSD1-targeted stemness-specific 
SOX2 enhancer in CSC-enriched 3-dimensional spheroids. Using high-throughput transcriptional data available 
from the METABRIC dataset, high expression of SOX2 was significantly more common in luminal-B and HER2-
enriched subtypes according to PAM50 classifier and in IntClust1 (high proliferating luminal-B) and IntClust 5 
(luminal-B and HER2-amplified) according to integrative clustering. Iadademstat significantly reduced 
mammospheres formation by CSC-like cells from a multidrug-resistant luminal-B breast cancer patient-derived 
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INTRODUCTION 
 
The transcription factor SOX2, a master regulator of 
embryonic and induced pluripotent stem cells [1–4], is 
causally related to tumor initiation, aggressiveness, and 
metastasis likely due to its ability to induce and 
maintain the stemness of cancer stem cells (CSC) [5, 6]. 
Given that a key mechanism of drug resistance relates 
to the incapacity of most standard therapeutics to 
eradicate the minor subpopulation of CSC with self-
renewal and seeding capacity, SOX2 has been 
suggested as an attractive anti-cancer target to prevent 
CSC-mediated clinical relapse [7, 8]. Unfortunately, the 
“undruggable” characteristics of transcription factors 
such as SOX2 has largely constrained the clinical 
potential of SOX2-centered therapeutic strategies in 
major cancer types. 
 
Pre-clinical approaches such as SOX2-targeting 
siRNAs, shRNAs, or miRNAs offer little therapeutic 
value because of their poor efficacy and delivery. By 
the same token, zinc-finger-based artificial transcription 
factors, which can modify the epi-transcriptional state 
of endogenous promoters with single locus specificity 
[9, 10], have been employed to reduce SOX2 mRNA 
and protein via targeting of proximal SOX2 promoters 
in cultured cancer cells and xenografts [7, 11], but their 
poor in vivo delivery to solid tumor tissue limits their 
usefulness for stable SOX2 down-regulation in a 
clinical context. Targeting of SOX2-related upstream/ 
downstream signaling pathways has become a more 
plausible approach, and pharmacological blockade of 
either the FBXW2-MSX2 axis with pevonedistat [12], 
the EGFR-STAT3 pathway with the cationic triphenyl-
methane pharmacophore gentian violet [13], or 
EGFR/SRC/AKT signaling with the EGFR inhibitors 
gefitinib and erlotinib and the Src inhibitor dasatinib 
[14], have been proposed as strategies to target human 
cancers with SOX2 overexpression. It is unknown, 
however, how much of the anti-cancer activity of these 
indirect approaches can be attributable to SOX2 
depletion. Moreover, the aforementioned strategies 
mostly target the proximal promoters of the SOX2 gene 
driving SOX2 expression in the differentiated states of 
cancer cells, and epigenetic re-activation of stemness-
specific enhancers that cause a subpopulation of tumor 
cells to shift towards a CSC state is unaffected. 
Mechanistically, such an approach can be achieved by 
inactivation of lysine-specific demethylase 1 
(LSD1/KDM1A), a flavin adenine dinucleotide (FAD)-
dependent homolog of the amine oxidase family that 
demethylates monomethyl or dimethyl lysine 4 (K4) of 
histone H3. LSD1 blockade with the small molecule 
inhibitor CBB1007 has been shown to enhance 
repressive H3K9 methylation at the stemness-specific 
enhancer of SOX2, thereby validating the notion that 
LSD1 might serve as a selective epigenetic target for 
therapeutic ablation of SOX2-driven cancer stemness 
[15]. Although CBB1007-like competitive LSD1 
inhibitors, which have been developed based on the 
structure of LSD1 with a peptide inhibitor derived from 
the N-terminal tail of histone H3 [16], might be 
considered good candidates to selectively target CSC 
with SOX2-driven pluripotent stem cell properties [17], 
most of them are in a preclinical stage.  
 
Iadademstat (formerly ORY-1001; Oryzon Genomics, 
Barcelona, Spain), a clinically proven, highly potent and 
selective covalent small-molecule inhibitor of LSD1 [18–
22], is an emerging therapeutic in hematological 
malignancies. Iadademstat has been shown to induce blast 
cell differentiation and reduce the leukemia-propagating 
stem cell compartment in acute myeloid leukemia (AML). 
Initial results from a Phase I/IIa clinical trial of 
iadademstat demonstrated its safety and good tolerability 
together with preliminary signs of anti-leukemic activity 
in refractory and relapsed AML [20]. Based on these 
findings, the Phase IIa ALICE study is currently ongoing 
in elderly patients with AML not eligible for intensive 
chemotherapy to combine iadademstat with standard of 
care azacytidine (https://www.clinicaltrialsregister.eu/ctr-
search/trial/2018-000482-36/ES). Beyond hematological 
cancers, blocking LSD1 with iadademstat has been 
proposed as a valid strategy in some solid tumors such as 
small-cell lung cancer (SCLC) and melanoma [21, 22]. 
Indeed, the Phase II CLEPSIDRA trial is recruiting 
relapsed SCLC patients to receive iadademstat in 
combination with platinum-etoposide chemotherapy 
(https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-
000469-35/ES). In addition, the capacity of iadademstat-
driven inhibition of LSD1 activity to activate immune 
responses has recently been proposed as a new means to 
overcome resistance to immune checkpoint inhibitors in 
melanoma [22]. Iadademstat-driven reversion of tumor-
driving undifferentiated cell states in genomically-diverse 
malignancies strongly supports the notion that LSD1 
might serve as a highly selective epigenetic target for the 
elimination of cancer cells with pluripotent stem cell-like 
properties [15, 16, 23, 24]. To test this hypothesis, we 
here investigated the ability of iadademstat to target 
xenograft but not of those from a treatment-naïve luminal-A patient. Iadademstat reduced the expression of 
SOX2 in luminal-B but not in luminal-A mammospheres, likely indicating a selective targeting of SOX2-driven 
CSC. The therapeutic relevance of targeting SOX2-driven breast CSC suggests the potential clinical use of 
iadademstat as an epigenetic therapy in luminal-B and HER2-positive subtypes. 
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SOX2-driven CSC in breast cancer, an unexplored cancer 
type for iadademstat-based therapy.  
 
Because the mechanism of action of iadademstat has 
been proposed to either impede the removal of the 
methyl group from mono-methylated and di-
methylated K4 and K9 of histone 3 on LSD1-targeted 
genes via a catalytic/enzymatic mechanism [18], or to 
promote enhancer activation of subordinate genes 
through the displacement of LSD1 from chromatin via 
a scaffolding/structural mechanism [19], we first 
computationally investigated the capacity of 
iadademstat to target the LSD1-bound FAD cofactor 
and to disturb the anchorage of LSD1 and its co-
repressor (RCOR1/CoREST) to chromatin. Second, 
because epigenetic re-activation of SOX2 expression 
via a pluripotency-specific enhancer can cause a 
subpopulation of tumor cells to dynamically acquire a 
CSC state, we evaluated the capacity of iadademstat 
to target the mammosphere-forming capacity -a well-
accepted surrogate reporter of CSC activity- in 
established in vitro models bearing distinct mutational 
landscapes (i.e., BRCA1-mutated basal-like MDA-
MB-436 and HER2 gene-amplified/luminal-B BT-474 
cell lines) but sharing a common dependency on 
SOX2 expression to maintain their CSC phenotype. 
Third, because SOX2 confers sensitivity to LSD1 
inhibition, we characterized the SOX2 expression 
pattern using the PAM50 classifier and the integrative 
clustering of transcriptional data available from the 
Molecular Taxonomy of Breast Cancer International 
consortium (METABRIC). Fourth, we finally 
evaluated the clinical relevance of iadademstat as a 
novel anti-SOX2 epigenetic breast cancer therapy by 
assessing its ability to impact both the expression of 
SOX2 and the tumorsphere-forming capacity of CSC-
like cells derived from breast cancer patient-derived 




Binding mode of iadademstat to the LSD1-CoREST-
histone H3 complex 
 
Two different models have been proposed to explain the 
mechanism of action of iadademstat. In the first, 
iadademstat rapidly and irreversibly binds the LSD1 
cofactor FAD in a manner analogous to the monoamine 
oxidase inhibitor tranylcypromine [18]. In the second, 
iadademstat physically separates LSD1/RCOR1 from 
the SNAG-domain transcription repressor GFI1 and 
chromatin in a cell-type-specific manner [19]. Taking 
advantage of the solved three-dimensional structure of 
LSD1 in a ternary complex with its histone peptide 
substrate and RCOR1/CoREST, we aimed to 
computationally explore a working model whereby 
iadademstat might operate via both a 
catalytic/enzymatic mechanism involving highly potent, 
direct targeting of the FAD cofactor (at lower 
concentrations), and a scaffolding/structural mechanism 
involving inhibition of the chromatin binding activity of 
LSD1/RCOR1 (at higher concentrations). Docking 
simulations of iadademstat in a crystal structure of 
human LSD1 (chain A) including RCOR1/CoREST 
(chain B) – a co-repressor that collaborates to 
demethylate mono- and di-methylated H3-K9 in 
nucleosomes – and a histone H3 peptide (chain C), 
produced eight clusters of docking poses (Figure 1). 
When the docking results were ranked according to the 
ascent of the binding energies for iadademstat (up to -
9.09 kcal/mol; Table 1), those clusters exhibiting the 
highest affinity (#1, #3, and #4, see inset on the top 
right of Figure 1) were in the nanomolar range and were 
predicted to occupy the same binding site as FAD in 
LSD1. Cluster #6 was predicted to interfere with the 
position of the histone H3 peptide, whereas clusters #7 
and #8, with affinities in the low micromolar range, 
were predicted to interact with both the LSD1 enzyme 
and RCOR1/CoREST.  
 
To add protein flexibility and provide additional 
information about different intra- and inter-molecular 
movements, we performed short molecular dynamics 
(MD) simulations over the course of 10 ns together with 
binding free energy calculations under the Molecular 
Mechanics Poisson-Boltzmann Surface Area (MM-
PBSA) approximation. The results highlighted the 
extremely high affinity of iadademstat at the FAD-
targeted clusters #3, and #4, which reached -103.909 
and -111.598 kcal/mol, respectively (Table 1).  
 
Using an AlphaScreen™ assay with a biotinylated 
histone H3 peptide methylated at lysine 4, purified 
LSD1, and a highly specific antibody that recognizes 
demethylated substrate, we confirmed the in vitro 
efficacy of iadademstat to dose-dependently suppress 
the demethylase activity of LSD1, with a mean IC50 of 
12 nmol/L (Supplementary Figure 1).  
 
Iadademstat specifically suppresses the 
mammosphere-formation potential of breast cancer 
stem cells 
 
One of the gold standards for evaluating the presence of 
CSC is their ability to form in vitro mammospheres in 
low-density non-adherent serum-free medium 
supplemented with growth factors [25, 26–29]. We 
assessed the anti-CSC activity of iadademstat in triple-
negative breast cancer (TNBC), a highly aggressive 
breast cancer subtype driven by highly enriched CSC, 
which are related to therapy resistance, tumor relapse, 
and metastasis [25, 30]. Accordingly, estrogen receptor 
 




Figure 1. Binding mode of iadademstat to LSD1. Top. The backbone of LSD1 (chain A)/REST corepressor 1 (chain B)/histone H3 
peptide (chain C) heterotrimeric complex is shown. For each cluster of the docked iadademstat (salmon color), only the molecule (spheres) 
with better binding energy is shown. The molecular docking was performed using the A and B chains in the absence of FAD and histone H3 
peptide; however, the clusters of docked iadademstat are shown superimposed on the position that would occupy both the FAD and the 
histone H3 peptide. The cluster number is also indicated. The insert on the left shows the peptide histone H3 (chain C, backbone as cartoon 
and side chains as sticks) and the FAD (represented as spheres and with the green carbons). The insert on the right shows only the best 
pose of iadademstat docked in each cluster and the situation of the histone H3 peptide. The clusters #1, #3 and #4 of iadademstat would 
occupy the same position of the FAD and are shown superimposed. Bottom. The detailed map of the molecular interactions of iadademstat 
in each cluster is detailed (see also Table 1). Each inset shows the detailed interactions of each compound docked to the LSD1 heterodimer, 
indicating the participating amino acids involved in the interaction and the type of interaction (hydrogen bonds, hydrophilic interactions, 
salt bridges, Π-stacking, etc).  
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Residues of the receptor that contact 
iadademstat 
1 -9.09 0.21811 5% -10.018 
Ile-284, Gly-285, Ser-286, Gly-287, Leu-307,  
Glu-308, Ala-309, Arg-310, Gly-315, Thr-588,  
Ala-589, Val-590, Arg-591, Thr-624, Leu-625,  
Pro-626, Val-629, Gln-632, Ala-636, Val-637,  
Trp-756, Ala-757 (chain A) 
2 -8.84 0.32872 9% -21.945 
Leu-625, Val-629, Leu-630, Lys-631, Gln-632,  
Gln-633, Pro-635, Ala-636, Val-637, Gln-638,  
Phe-639, Val-640, Pro-642, Leu-643, Thr-648 
(chain A) 
3 -8.75 0.38632 5.5% -103.909 
Gly-285, Ser-286, Gly-287, Val-288, Ser-289,  
Gly-290, Glu-308, Ala-309, Arg-310, Gly-314,  
Gly-315, Arg-316, Val-317, Thr-624, Leu-625,  
Pro-626, Trp-756, Gly-800, Glu-801,  
Thr-810, Val-811, Ala-814 (chain A) 
4 -8.74 0.39379 17% -111.598 
Arg-316, Leu-329, Gly-330, Ala-331, Met-332,  
Val-333, Thr-335, Tyr-571, Leu-659, Asn-660,  
Lys-661, Trp-751, Ser-760, Tyr-761, Ala-809,  
Thr-810, Val-811 (chain A) 
5 -7.95 1.49000 4.5% -68.647 
Ala-178, Phe-179, Arg-182, Leu-183, Pro-184,  
His-185, Gly-338, Gly-339, Asp-557, Phe-558,  
Glu-559, Phe-560, Thr-561, Tyr-807 (chain A) 
6 -7.92 1.57000 2.5% -29.621 
Thr-335, Ala-539, Asn 540, Trp-552, Asp-555,  
Phe-558, Glu-559, Phe-560, Tyr-761, Ser-762,  
Tyr-763, Val-764, Asn 806, Tyr-807, Pro-808,  
Ala-809, Thr 810, His-812 (chain A) 
7 -7.09 6.40000 16.5% -18.198 
Lys-481, Ser-482, His-484, Arg-485, Thr-488  
(chain A) and Leu-372, Pro-373, Glu-374,  
Val-375, Ile-376, Gln-377, Asp-407,  
Val-408, Gly-410 (chain B) 
8 -6.33 22.98000 8% -32.309 
Tyr-391 (chain A) and Lys-309,  
Pro-310, Pro-311, Lys-312, Gly-313,  
Met-314, Phe-315, Leu-316,  
Ser-317, Gln-318 (chain B) 
For the best-docked iadademstat molecule of each cluster, the Gibbs free energy, the dissociation constant, the number of 
molecules members (as %), and the MM/PBSA solvation binding energy are shown. 
 
(ER)-negative/progesterone receptor (PR)-negative/ 
HER2-negative BRCA1mut/PTENmut MDA-MB-436 
cells, which can form smooth and round spheres in 
suspension culture [25] and are dependent on SOX2 
expression to maintain their CSC phenotype [31], were 
used in the Cell2Sphere™ assay to evaluate the impact 
of iadademstat on the ability of CSC to survive and 
proliferate as floating microtumors. Specifically, we 
examined the effects of iadademstat on the total 
number, size, and aspect of MDA-MB-436 mammo-
spheres growing under stem cell-selective conditions. 
Compared with the untreated controls, exposure to 
graded concentrations of iadademstat resulted in a dose-
dependent decrease in the total number of 
mammospheres (IC50 = 3.98 µmol/L; Figure 2). 
Notably, the strong decrease in mammosphere 
formation by iadademstat was not due to non-specific 
toxicity, as MTT-based cell viability assays run in 
parallel in 10% serum-supplemented adherent 
conditions showed no significant cytotoxic activity of 
iadademstat, even when employing concentrations as 
high as 30 µmol/L – a dose that completely prevented 
mammosphere formation in MDA-MB-436 cells 
(Figure 2). 
 
Iadademstat suppresses pluripotency enhancer-
driven activation of SOX2 in breast cancer stem cells 
 
LSD1-blocking compounds are known to differentially 
target pluripotent cancer cells including teratocarcinoma, 
embryonic carcinoma, and seminoma, or embryonic stem 
cells that express SOX2, while having minimal growth-
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inhibitory effects on non-pluripotent cancer or normal 
somatic cells [15, 16, 23]. We therefore envisioned that 
iadademstat might suppress CSC function by repressing 
the re-activation of SOX2 in breast CSC, a transcriptional 
phenomenon that specifically occurs through activation 
of the distal enhancer of the SOX2 promoter that also 
controls SOX2 transcription in pluripotent stem cells [32, 
33]. When we transfected tamoxifen-resistant, luminal-
B/HER2+ BT-474 cells [34] with a luciferase reporter 
vector containing the SOX2 distal enhancer region, we 
observed a robust induction (9.2-fold on average) of 
reporter activity in mammosphere cultures when 
compared with the adherent culture control (Figure 3A). 
Of note, the enhancer-driven transcriptional activation of 
SOX2 differentially occurring in mammosphere cultures 
was dose-dependently suppressed by iadademstat (up to 
80% reduction at 10 µmol/L; Figure 3A). Importantly, 
iadademstant-driven SOX2 silencing drastically reduced 
the number of BT-474 mammospheres (data not shown).  
Iadademstat fails to target ALDH+ breast cancer 
stem cells 
 
We next tested whether the mechanism of action of 
iadademstat to specifically target mammosphere-
forming CSC-like cells might be due to a more general 
phenomenon involving drivers of breast cancer 
stemness other than SOX2. Thus, we evaluated its 
capacity to target cells with high levels of aldehyde 
dehydrogenase-1 (ALDH1), a biomarker that has been 
suggested to label a tumorigenic cell fraction capable of 
self-renewal [35, 36]. ALDH1+ cell subpopulations 
enriched for cancer-initiating activity can be readily 
identified by flow cytometry using the Aldefluor® 
reagent, which quantifies ALDH activity by measuring 
the conversion of the ALDH substrate BODIPY 
aminoacetaldehyde to the fluorescent product BODIPY 
aminoacetate. Using HER2-overexpressing BT-474 




Figure 2. Iadademstat suppresses mammosphere formation in a basal-like established cell line. Figure shows representative 
microscope representations (×2.5 magnification) of mammospheres formed by MDA-MB-436 cells growing in sphere medium for 6 days in 
the absence or presence of graded concentrations of iadademstat. The number of mammospheres (>100 µm diameter) is expressed as 
means (columns)  SD (bars). MTT uptake-based measurement of cell viability is expressed as percentages uptake (OD570) relative to 
untreated controls (=100% cell viability). The results are expressed as percentages means (columns)  SD (bars). *P < 0.05 and **P < 0.005, 
statistically significant differences from the untreated (control) group. 
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ALDH1+ cells (>50%), we detected a decrease in the 
proportion of ALDH1+ cells following 72 h treatment 
with increasing concentrations of iadademstat (up to 
35% decrease at 25 µmol/L iadademstat) as compared 
with vehicle-treated controls (Figure 3B). 
 
SOX2 expression status associates with luminal-B 
and HER2-positive breast carcinomas 
 
Comprehensive comparison of molecular portraits 
between cell lines and breast cancer tumors confirmed 
the luminal-B intrinsic subtype classification of the 
ER+/HER2+ BT-474 cell line but revealed that the basal-
like cell line MDA-MB-436 exhibits similar protein 
features to those of the luminal-A breast cancer subtype 
[37]. Because SOX2-overexpressing cells are particularly 
sensitive to LSD1 inhibitors [15, 17], we explored the 
possibility that SOX2 expression might associate with the 
luminal entity across breast tumor subtypes. When we 
examined the expression status of SOX2 in two sets of 
breast cancer cell lines organized by luminal, basal-A 
(i.e., basal-like breast cancer intrinsic subtype), and 
basal-B (i.e., claudin-low breast cancer intrinsic subtype) 
sub-classes [38, 39], most of the SOX2-overexpressing 
breast carcinoma cell lines were found to belong to the 




Figure 3. Iadademstat inhibits stemness-associated SOX2 expression in a luminal-B/HER2+ established cell line. (A) Schematic 
representation of SOX2 promoter structure indicating the proximal core promoter region and the location of the distal enhancer, which is 
induced exclusively upon CSC-driven mammosphere formation but not in cell-adherent differentiating conditions. Results are expressed as 
fold-induction of mammosphere culture-associated SOX2 reporter activity above adherent culture control in the absence or presence of 
graded concentrations of iadademstat. The results are expressed as percentages means (columns)  SD (bars). *P < 0.05 and **P < 0.005, 
statistically significant differences from the untreated (control) group. (B) Representative Aldefluor® assay to identify BT-474 cells with high 
ALDH activity (ALDH+) in the absence or presence of graded concentrations of iadademstat for 3 days. The ALDH inhibitor 
diethylaminobenzaldehyde (DEAB) was used as negative control. Monolayer cultures were fed with iadademstat on day 1. (Note: 1 µmol/L 
FM19G11, an epigenetic repressor of key genes involved in stemness including SOX2 [98], was employed as a positive control). 
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We then extracted breast cancer date sets from the 
Molecular Taxonomy of Breast Cancer International 
Consortium (METABRIC) [40, 41] to explore the 
association between SOX2 expression and multiple 
breast cancer subtypes. When the METABRIC breast 
cancer data set was classified into each of the four Gene 
Expression prognostic Index Using Subtypes (GENIUS) 
subgroups using a 3-gene classifier (i.e., HER2+, ER-
/HER-, ER+/HER2- high proliferation, ER+/HER2- low 
proliferation) [42, 43], SOX2 expression was found to 
be significantly higher in the HER2+ and ER+/HER2- 
high proliferation (luminal B-like) subgroups (Figure 
4B, left panel). When the METABRIC breast cancer 
data set was classified into each of the five intrinsic 
subtypes (i.e., luminal-A, luminal-B, HER2-enriched, 
basal-like, and normal-like) using the research-based 
50-gene prediction analysis of microarray (PAM50) 
classifier [44], SOX2 expression was found to be 
significantly higher in the luminal-B and HER2-
enriched subtypes (Figure 4B, middle panel). When the 
METABRIC data set was classified into each of the 10 
integrative clusters (IntClust1-10) each associated with 
distinct somatic aberrations (CNAs) and gene 
expression changes [45, 46], the transcript level of 
SOX2 was found to be significantly upregulated in the 
IntClust1, which is constituted by ER-positive tumors 
predominantly classified into the higher proliferation 
luminal-B intrinsic subtype, and in the IntClust5, which 
mostly encompasses HER2-amplified breast composed 
of both HER2-enriched and luminal-B intrinsic 
subtypes (Figure 4B, right panel).  
 
Iadademstat suppresses the formation of CSC-
enriched mammospheres derived from a multidrug-
resistant luminal-B breast cancer patient in a SOX2-
related manner 
 
Because patient-derived xenograft (PDX) tumor models 
more faithful recapitulate human tumor biology and 
drug responsiveness than established human cancer cell 
lines [47, 48], we employed CSC-enriched mammo-




Figure 4. SOX2 expression is enriched in luminal-B and HER2-positive breast cancer subtypes. (A) Relative enrichment of SOX2 
expression (213721_at) in breast cancer cell lines organized by luminal, basal A, and basal B sub-classes [38, 39]. (B)  Box plots presents the 
SOX2 gene expression in primary breast tumors from the METABRIC project classified in distinct subtypes using 3-gene (left), PAM50 (middle), 
and integrative clusters (right) classifiers. The color line presents median, box shows interquartile region and whiskers – the highest (max) 
and the lowest (min) value.  
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from excised PDX tumors under adherent-free 
conditions [49] to test the anti-CSC activity of 
iadademstat in a clinically-relevant scenario (Figure 5). 
The BRE-0188 (ER+/PR+/HER2-) PDX model was 
generated from a clinical sample obtained from a 65-
year-old female with luminal-A invasive ductal 
carcinoma with the presence of lymph node metastases. 
The patients had not received any chemotherapy or 
radiotherapy prior to surgery. The BRE-0192 
(ER+/PR+/HER2-) PDX model was generated from a 
clinical sample obtained from a 45-year-old female with 
luminal-B invasive lobular breast carcinoma with the 
presence of lymph node metastases [50]. The patient 
was a poor responder to prior therapies, including 
epirubicin, 5-fluorouracil, cyclophosphamide, taxotere, 
paclitaxel, bevacizumab, and gemcitabine.  
 
Iadademstat treatment failed to decrease the number of 
mammospheres originated from CSC-like cells derived 
from the luminal-A BRE-0188 PDX (Figure 5A); the size 
of BRE-0188 mammospheres, however, was 
significantly decreased after treatment with iadademstat. 
Treatment of BRE-0188 mammospheres cultures with 
iadademstat failed to alter SOX2 expression. Conversely, 
iadademstat treatment significantly decreased the number 
but not the size of mammospheres originated from the 
multidrug-resistant CSC-like cells derived from the 




Figure 5. Iadademstat targets SOX2-driven CSC in breast cancer patient-derived xenografts. Cell2Sphere™ assays using BRE-0188 
(A) and BRE-0192 (B) PDXs were performed as per the manufacturer’s instructions (http://stemtektherapeutics.com/en/cell2sphere#cell2 
sphere_kit). Increasing concentrations of iadademstat were added to sextuplicate sets of wells on day 1. ImageJ was used to quantify the 
number (left panels) and size (middle panels; central lines indicate mean values) of 9-day-old mammospheres. Right panels. Total RNA from 
untreated and iadademstat-treated mammosphere cells was evaluated in technical triplicates for the abundance of SOX2 (Hs01053049_s1) 
relative to housekeeping gene 18S (Hs99999901_s1). The transcript abundance was calculated using the delta Ct method (i.e., the difference 
of Ct value between the target SOX2 gene and the endogenous 18S control) and presented as relative quantification.  
 
www.aging-us.com 4803 AGING 
treatment with iadademstat notably reduced the 
expression of SOX2 in mammospheres collected from 




We provide the first evidence that the clinically proven 
inhibitor of LSD1 iadademstat can be used to 
circumvent the challenge of pharmacologically 
manipulating the epigenetic re-activation of SOX2 that 
causes a subpopulation of tumor cells to shift towards a 
CSC state, which has constrained the clinical relevance 
of SOX2-centered therapeutic strategies in major cancer 
types such as breast cancer. The therapeutic potential of 
targeting SOX2-driven CSC supports the clinical use of 
iadademstat as a novel anti-SOX2 epigenetic breast 
cancer therapy, particularly in SOX2-enriched luminal-
B and HER2-positive subtypes. 
 
Some malignant tumors such as breast carcinoma depend 
on SOX2 for their tumor-initiating ability [34, 51–53]. 
Elevated LSD1 levels are associated with enhanced 
SOX2 expression, and SOX2-overexpressing cells are 
particularly sensitive to LSD1 inhibitors. Accordingly, 
LSD1 has been proposed as a selective epigenetic target 
for therapy in SOX2-expressing cancers, particularly in 
those carcinomas in which high SOX2 expression occurs 
via 3q26 chromosomal amplification (e.g., lung SCLC, 
serous ovarian carcinoma, cervical, head and neck, oral, 
and esophageal carcinomas [6]). However, such LSD1 
inhibitor-based therapeutic strategies might become even 
more relevant as cancer is entering a new era where the 
concept of cellular/phenotypic plasticity involving the 
dynamic interconversion of cells with and without CSC 
states is challenging how we treat and understand tumors 
relapse [54–61]. LSD1 controls SOX2 expression by 
binding to its distal enhancer, which drives SOX2 
activation in pluripotent stem-like cells including CSC 
[15, 33, 62]. Pharmacological blockade of LSD1 
selectively promotes methylation of H3K4 and H3K9 
within the regulatory (enhancer) region of the SOX2 
promoter, suppressing SOX2 activity and stimulating cell 
differentiation by augmenting H3K4 methylation on the 
promoters of differentiation genes [15]. In a process that 
is not mutually exclusive, the differentiation genes that 
are directly controlled by LSD1 can indirectly inhibit the 
expression of SOX2 that confers stem cell-like traits to 
breast cancer cells [63].  Indeed, the therapeutic 
implications of our current findings with the LSD1 
iadademstat might involve molecular scenarios in which 
the epigenetic re-activation of SOX2 within a group of 
transformed cells in response to microenvironmental 
cues, stochastic genetic and epigenetic alterations, and/or 
treatment-imposed selective pressures can cause them to 
shift toward a CSC state, LSD1-driven aberrant 
activation of SOX2 via stemness-specific enhancers 
irrespective of their mutational landscape (e.g., BRCA1-
mutated basal-like, HER2 gene-amplified), but also in 
certain breast cancer intrinsic subtypes that might be 
intrinsically addicted to the major role of SOX2 in self-
renewal growth and expansion of CSC-like cells (i.e., 
luminal-B and HER2-positive). Such clinically relevant 
specificity of the LSD1 inhibitor iadademstat against 
SOX2-driven CSC was confirmed not only in established 
breast cancer cell lines that are dependent on SOX2 
expression to maintain their CSC phenotype [31, 34] but 
also in CSC-enriched mammospheres generated by 
growing single-cell suspensions from excised PDX 
tumors.  
 
The fact that the SOX2 reporter assay detects variations in 
SOX2 transcription regardless of the proportion of cells 
expressing a CSC marker along with the ability of 
iadademstat-induced knockdown of SOX2 to sharply 
decrease the quantity of CSC-like cells capable of self-
renewal in vitro but not to completely suppress 
subpopulations with high enzymatic activity of ALDH1 
(ALDH1high), which has been shown to mark a breast 
cancer population enriched for proliferating CSC, 
strongly suggest that the anti-CSC activity of iadademstat 
might be restricted to SOX2-driven CSC bio-behaviors 
(e.g., 1-3% of all luminal-B/HER2+ BT-474 cells) that 
do not necessarily overlap with that of ALDHhigh 
proliferating cells. Using CSC-enriched mammospheres 
obtained by growing single-cell suspensions from excised 
PDX tumor under adherent-free conditions, treatment 
with iadademstat resulted in significantly reduced 
mammosphere formation (but not reduced mammosphere 
size) in a multi-drug resistant luminal-B breast carcinoma 
and in significantly reduced mammosphere size (but not 
reduced mammosphere number) in a treatment-naïve 
luminal-A breast cancer. The number of mammospheres 
reflects the quantity of CSC-like cells capable of self-
renewal in vitro, while the size of mammospheres is an 
indirect measure of the self-renewal capacity of each 
mammosphere-generating cell; thus, cell proliferation 
during mammosphere growth determines the size of the 
mammospheres [64–66]. Taking together, these results 
indicate that iadademstant inhibited CSC-driven 
mammosphere formation efficiency through suppressing 
LSD1/SOX2 axis in a luminal-B breast carcinoma, 
whereas the size of mammospheres in a luminal-A tumor 
was regulated through other underlying proliferative 
mechanism via LSD1. Accordingly, treatment of 
mammospheres from the luminal-B (but not the luminal-
A) breast cancer patient with iadademstat significantly 
reduced the expression of SOX2, likely indicating a 
selective targeting of SOX2-driven CSC. The therapeutic 
potential of targeting SOX2-driven CSC supports the 
clinical use of iadademstat as a novel anti-SOX2 
epigenetic breast cancer therapy, particularly in endocrine 
therapy-resistant luminal-B cases -which are known 
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employ SOX2 to increase the proportion of CSC-like 
cells, rendering them insensitive to tamoxifen [34]- and 
in HER2-positive disease –in which SOX2 over-
expression correlates with poor differentiation [67] and 
HER2-targeted therapies such as trastuzumab fail to 
eliminate SOX2-overexpressing CSC [68]. We have to 
acknowledge that the LSD1/SOX2 axis may represent a 
provocative potential target for CSC elimination not only 
in luminal-B and HER2-positive tumor but also in the 
basal-like subtype, which can also be found in the SOX2-
overexpressing IntClust5 [46]. In this regard, because 
SOX2 reactivation has been shown to depend on the 
recruitment of the tumor suppressor protein BRCA1 to 
the pluripotency-related distal enhancer in the SOX2 
promoter and concomitant modification of H3K4 and 
H3K9 at the same enhancer [62], our findings in basal-
like MDA-MB-436 cells support the idea that BRCA1-
mediated predisposition to breast and ovarian cancer [69] 
might involve a controlled loss of SOX2 expression, 
establishing a direct link between LSD1-regulated 
expression of SOX2, acquisition of stem-like cell 
phenotypes, and BRCA1-related breast/ovarian cancer 
initiation. Indeed, SOX2 is frequently gained in BRCA1 
germline mutated tumors and is preferentially expressed 
in sporadic basal-like phenotypes having similar 
phenotypic and clinical characteristics to breast cancer 
arising in BRCA1 mutation carriers. Accordingly, SOX2 
might play a driver role in the development of their less 
differentiated/stem cell-like phenotypic traits charac-
teristics of the basal-like breast cancer phenotype [70]. 
Moreover, SOX2 overexpression occurs not only in 
high-grade serous ovarian tumors, but also in pre-
malignant, fallopian tube epithelial cells from 
BRCA1/BRCA2 mutation carriers who underwent 
prophylactic salpingo-oophorectomy [71] – opening the 
possibility for considering LSD1-targeted epigenetic 
approaches such as iadademstat for breast/ovarian 
cancer prevention.  
 
SOX2 activation has proved instrumental for the plastic 
acquisition of aberrant stemness properties in cancer 
cells. Accordingly, certain CSC bio-behaviors can be 
defined as rare therapy-resistant, self-renewing cancer 
cells that aberrantly express SOX2, which might 
provide specificity for CSC-targeted drug screening. 
The use of fluorescence protein expression-based 
transcriptional reporters for activation of the LSD1-
regulated enhancer element of the SOX2 gene promoter 
can specifically identify cells with tumor-initiating 
activity; compounds that would be capable of impeding 
SOX2 activation might be viewed as valuable 
candidates for drugs aimed to target CSC. In this regard, 
our findings unravel for the first time the ability of 
iadademstat to inhibit an LSD1-targeted distal enhancer 
that specifically controls the expression of the stem cell 
transcription factor SOX2 in pluripotent stem cells, 
thereby suppressing the re-activation of SOX2 
exclusively occurring in mammosphere-initiating breast 
CSC. The ability of iadademstat to efficiently and 
specifically target the on/off LSD1-driven SOX2 
regulatory process that provides higher tumorigenic 
potential to cells with an epigenetically acquired CSC 
phenotype [61, 72] might open new therapeutic 
horizons that incorporate iadademstat in the anti-breast 
cancer armamentarium. We further propose that 
iadademstat might functionally deplete tumor-initiating 
CSC-like cellular states that sustain tumorigenicity by 
impacting on fundamental controllers of cell fate 
choice, an epigenetic mechanism involving both the 
downregulation of SOX2 and the re-activation of 
epigenetically suppressed differentiation programs in 
SOX2-enriched breast cancer subtypes such as 
Luminal-B and HER2-positive.  
 
Furthermore, we are rapidly appreciating that nuclear 
reprogramming-like phenomena inducing the 
acquisition of epigenetic plasticity and phenotype 
malleability should be viewed as a fundamental element 
of a tissue’s capacity to undergo successful repair, aging 
degeneration or malignant transformation [73–77]. 
Thus, chronic or unrestrained cell plasticity would drive 
aging phenotypes by impairing the repair or the 
replacement of damaged cells and such uncontrolled 
phenomena of in vivo reprogramming might also 
generate CSC-like cellular states [73–77]. 
Pharmacological tools selectively targeting the LSD1-
SOX2 axis might be appropriate to experimentally 
uncouple the apparently counterintuitive capacity of 
LSD1 blockade to promote reprogramming phenomena 
by regulating the balance between pluripotency and 
differentiation [78–83] while preventing SOX2-driven 
cancer stemness. This would raise the possibility of 
pharmacologically managing, in the appropriate 
direction and intensity, the physiological versus 
pathological processes of SOX2-related reparative 
cellular reprogramming in aging and cancer.  
 




The human histone demethylase LSD1 (UniProt code 
O60341)/REST corepressor 1 (UniProt code 
Q9UKL0)/histone H3 peptide (UniProt code P68431) 
ternary complex structure (3 Å resolution, PDB code 
2X0L) was obtained from the Research Collaboratory 
for Structural Bioinformatics Protein Data Bank (PDB). 
The molecular structure of iadademstat was obtained 
from PubChem (PubChem_ID: 71543365). The specific 
edition of the LSD1 protein structure involving the 
removal of water, FAD, and histone H3 peptide, was 
made using PyMol 2.0 software (PyMOL Molecular 
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Graphics System, v2.0 Schrödinger, LLC, at 
http://www.pymol.org/) without further optimization.  
 
Molecular docking analysis of iadademstat against 
LSD1 was performed as previously described [84–88]. 
The selected protein structure was subjected to 
geometry optimization using the repair function of the 
FoldX algorithm [89]. To search for potential binding 
sites of iadademstat, a global molecular docking 
procedure was performed with AutoDock/Vina using 
YASARA v19.4.27 software [90, 91], where a total of 
999 flexible docking runs were set and clustered (7 Å) 
around the putative binding sites. The YASARA pH 
command was set to 7.4. The docking software has a 
scoring function to give an approximate calculation of 
the Gibbs free energy variation (ΔG, kcal/mol) between 
LSD1 and iadademstat in each binding pose, with more 
positive energy values indicating stronger binding [92]. 
All the values were included in the corresponding table 
with a negative sign; only the ΔG value for the best 
compound docked in each cluster is shown in Table 1. 
To calculate this parameter, which is used to rank 
compounds, Autodock Vina uses a force field scoring 
function that considers the strength of electrostatic 
interactions, hydrogen bonding between all atoms of the 
two binding partners in the complex, intermolecular van 
der Waals forces, and also solvation and entropy 
contributions [93]. Docking results usually cluster 
around certain hot spot conformations. Two complexed 
compounds were considered to belong to different 
clusters if the ligand Root-Mean-Square Deviation of 
their atomic positions was greater than a minimum of 6 
Å. Dissociation constants were recalculated from the 
average binding energy of all compounds of each 
cluster. The number of iadademstat-docked molecules 
included in each compound cluster is indicated as 
"members", as a percentage in Table 1. The key 
residues of LSD1 interacting with iadademstat in each 
cluster were detected using also YASARA v19.4.27 
software [90, 91]. All of the figures were prepared using 
PyMol 2.0 software and all interactions were detected 
using the PLIP algorithm [94].  
 
Molecular dynamics simulations 
 
YASARA dynamics v19.4.27 was also used for all the 
MD simulations with AMBER14 as a force field. The 
simulation cell was allowed to include 20 Å 
surrounding the protein and filled with water at a 
density of 0.997 g/mL. Initial energy minimization was 
carried out under relaxed constraints using steepest 
descent minimization. Simulations were performed in 
water at constant pressure-constant temperature (25°C) 
conditions. To mimic physiological conditions, counter 
ions were added to neutralize the system; Na+ or Cl- 
were added in replacement of water to give a total NaCl 
concentration of 0.9% and pH was maintained at 7.4. 
Hydrogen atoms were added to the protein structure at 
the appropriate ionizable groups according to the 
calculated pKa in relation to the simulation pH (i.e., a 
hydrogen atom will be added if the computed pKa is 
higher than the pH). The pKa was computed for each 
residue according to the Ewald method [95]. All 
simulation steps were run by a preinstalled macro 
(md_run.mcr) within the YASARA suite. Data were 
collected every 100 ps. 
 
TMM/PBSA was implemented with the YASARA 
macro md_analyzebindenergy.mcr to calculate the 
binding free energy with solvation of iadademstat, 
complex, and free protein for the LSD1 form 
complexes. The binding free energy (kcal/mol) was 
expressed according to the following equation: 
 
Ebinding = [poterec(i) + solverec(i) + potelig + solvelig] 
- [potecmp(i) + solvecmp(i)] 
 
where i is the position number, “pote” is the potential 
energy for the complex (potecmp), free protein 
(poterec), or free ligand (potelig), and “solve” is the 
solvation energy for the complex (solvecmp), free 
protein (solverec), or free ligand (solvelig). More 
positive binding free values indicate better binding. 
 
LSD1 enzymatic activity 
 
Enzymatic reactions were performed in an AlphaScreen 
format in duplicate at room temperature for 60 minutes 
in a 10 µL mixture containing assay buffer, histone H3 
peptide substrate, LSD1 (BPS#50103, lot#130806-D) 
enzyme, and iadademstat (RG-6016, Cat. No. S7795, 
Selleckchem.com). The 10-µL reactions were carried 
out in 384-well Optiplates (Perkin Elmer Life Sciences, 
Waltham, MA). A serial dilution of the compounds was 
first performed in 3.3% DMSO/assay buffer. From this 
step, 3 µL of iadademstat was added to 4 µL of enzyme 
and incubated for 30 minutes at room temperature. 
After this incubation, 3 µL of substrate was added to 
initiate the reaction. The final DMSO concentration was 
1%. After the reaction, 5 µL of anti-mouse acceptor 
beads (Perkin Elmer, diluted 1:500 with 1× detection 
buffer) or 5 µL of anti-rabbit acceptor beads (Perkin 
Elmer, diluted 1:500 with 1× detection buffer) and 5 µL 
of primary antibody (BPS#52140E,F, diluted 1:200 with 
1x detection buffer) were added to the reaction mix. 
After brief shaking, the plate was incubated for 30 
minutes. Finally, 10 µL of AlphaScreen streptavidin-
conjugated donor beads (Perkin Elmer, diluted 1:125 
with 1× detection buffer) were added. After 30 minutes, 
the samples were measured in the AlphaScreen 
microplate reader (EnSpire Alpha 2390 Multilabel 
reader, Perkin Elmer).  
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The AlphaScreen intensity data were analyzed and 
compared using Graphpad Prism software (GraphPad 
Software Inc., San Diego, CA). In the absence of 
iadademstat, the AlphaScreen or fluorescence intensity 
(Ft) was defined as 100% activity. In the absence of 
enzyme, the intensity (Fb) was defined as 0% activity. The 
percent activity in the presence of iadademstat was 
calculated according to the following equation: %activity 
= (F-Fb)/(Ft-Fb), where F=the A-screen intensity in the 
presence of iadademstat. Once A-screen data were 
converted to LSD1 activity (%), those values were then 
plotted against a series of iadademstat concentrations 
using non-linear regression analysis of sigmoidal dose-
response curves generated with the equation Y=B+(T-
B)/1+10((LogEC50-X)×Hill Slope), where Y=percent activity, 
B=minimum percent activity, T=maximum percent 
activity, X=logarithm of compound and Hill Slope=slope 
factor or Hill coefficient. The IC50 value was determined 
as the concentration of iadademstat causing a half-
maximal inhibition of control activity. 
 
SOX2 profiling in breast cancer datasets 
 
We interrogated the publicly available METABRIC 
breast cancer dataset in the United Kingdom and Canada 
[40], in which mRNA expression was measured using the 
Illumina HT-12v13 platform and CNA with the 
Affymetrix SNP 6.0 array. Gene-level expression files 
from METABRIC were downloaded from the cBioportal 
for Cancer Genomics (https://www.cbioportal.org/). We 
used the 3-gene, PAM50, and integrative clusters 
subtypes provided in the METABRIC dataset.  
 
Breast cancer xenograft models 
 
For generation of BRE-0188 and BRE-0192 PDX 
models, all clinical samples were collected under 
written informed consent (according to the Declaration 
of Helsinki) and a declaration for commercial use of the 
samples from the Consultative Committee for the 
Protection of Persons in Biomedical Research 
(CCPPRB) of Dijon University Hospital under 
authorization by a French Ministry of Higher Education, 
Research and Innovation for human tissue collection, 
and redistribution (CSP articles L 1243-3, L 1243-4, 
and L 1245-5). PDX tumors were passaged by serial 




Mammosphere formation was monitored using 
Cell2Sphere™ assays (StemTek Therapeutics, Bilbao, 
Spain) as per the manufacturer’s instructions [96, 97]. 
Graded concentrations of iadademstat were added to 
triplicate sets of wells on day 1 and the number of either 
6- (MDA-MB-436, BT-474) or 9-day-old (BRE-0188, 
BRE-0192 PDX) mammospheres was recorded as a 
measurement of CSC content. Images were recorded 
using a BioTek Cytation 5 image cytometer at 2.5× 
magnification. Prior to image acquisition, spheroid 
cultures were stained with a fluorescent vital dye to 
increase the accuracy of spheroid detection and analysis. 
The system was then set to count number, size, and 
aspect ratio of the objects. Thresholds were set to >100 
µm in size and 0.4 as aspect ratio (with 1 being the aspect 





Cell viability was determined using a standard 
colorimetric MTT-based reduction assay 72 h after 
exposure to graded concentrations of iadademstat.  
 
Aldefluor® activity assay 
 
The Aldefluor® assay was performed as per the 
manufacturer’s instructions (StemCell Technologies, 
Vancouver, BC, Canada), with or without the addition 
of graded concentrations of iadademstat for 72 h. 
Analysis was performed using a MACSQuant® 
Analyzer 10 flow cytometer (Miltenyi Biotec, Bergisch 
Gladbach, Germany) for data acquisition.  
 
SOX2 enhancer reporter assay 
 
BT-474 cells were transfected with 5 µg of pGL3 Luc 
control (Promega, Madison, WI, USA) or pGL2-Sox2-
enhancer-Luc reporter plasmids [32, 33] using 
Lipofectamine Plus (Invitrogen, Carslbad, CA). Twenty-
four hours after transfection, the culture was split into 
two parts: one part was seeded in two-dimensional 
adherent culture plates and the other part was cultured in 
non-adherent culture conditions to allow mammosphere 
formation, in the absence or presence of graded 
concentrations of iadademstat. After 48 h, cells were 
harvested and luciferase activity was measured in 
duplicate with the Glomax 20/20 luminometer (Promega) 
and normalized by protein concentration in the extracts. 
Results were expressed as fold induction of sphere 
culture reporter activity above adherent culture control. 
 
Quantitative real-time PCR 
 
Total RNA was extracted from mammosphere cells 
using the Qiagen RNeasy Kit according to the 
manufacturer’s instructions. One microgram of total 
RNA was reverse-transcribed to cDNA using the 
Reaction Ready™ First Strand cDNA Synthesis Kit 
(SABiosciences, Frederick, MD). PCR arrays were 
processed according to the SABiosciences RT-PCR 
manual and analyzed using an Applied Biosystems 
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7500 Fast Real-Time PCR System with an automated 
baseline and threshold cycle detection. The data were 
interpreted using the web-based PCR array analysis tool 




All statistical analyses were performed using GraphPad 
Prism software. Cell-based experimental data are 
presented as mean ± S.D. Comparisons of means of ≥ 3 
groups were performed by analysis of variance 
(ANOVA) and the existence of individual differences, 
in case of significant F values at ANOVA, were 
assessed by multiple contrasts. The expression of SOX2 
in the breast cancer subtypes (METABRIC dataset) was 
examined using one-way ANOVA (Kruskal-Wallis) 
with Dunnett’s test. P values < 0.05 were considered to 
be statistically significant (denoted as *). All statistical 
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Supplementary Figure 1. Iadademstat inhibits LSD1 activity. Dose-response curves of LSD1 demethylation activity were created by 
plotting AlphaScreen signals as the function of iadademstat concentration. Circles and error bars represent mean values and S.D., 
respectively. Data are representative of two independent experiments (*P < 0.05).  
 
